Featuring news, events and industry trends
Cognition Therapeutics in the News

Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022

Headquartered in Purchase, Cognition Therapeutics, Inc. a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 (σ-2) receptor modulator in development for Alzheimer’s disease and other neurodegenerative disorders. Specifically, data will be presented from the Phase 1b SNAP study (COG0104; NCT03522129) and an interim analysis from the Phase 2 SHINE study (COG0201; NCT03507790) in two posters at the upcoming AD/PD™ 2022: the 16th International Conference on Alzheimer’s & Parkinson’s Diseases.

Cognition Therapeutics Announces Participation in March Investment Conferences

Cognition Therapeutics, Inc., announced the Company’s president and CEO, Lisa Ricciardi, will be participating at two upcoming conferences, details of which follow.

Event: Oppenheimer 32ndAnnual Healthcare Conference
Date: March 16, 2022
Time: 4:00 p.m. ET
Access: A live webcast of the presentation will be available on the “Events and Presentations” section of the Cognition Therapeutics website for a period of 90 days following the conference

Event: Sachs Neuroscience Innovation Forum
Panel: Latest Developments in Alzheimer’s Disease and Dementia
Date: March 22, 2022
Time: 10:00 a.m. ET
Access: The panel will be available live and on demand to registered participants through the Sachs Forum website.

Lisa Ricciardi will be available for one-on-one meeting during both conferences. To schedule a one-on-one meeting, please contact your respective event representative or Lisa Sher at lsher@tiberend.com.
Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

Harrison headquartered, Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of small protein therapeutics to address difficult-to-treat cancers, announced two abstracts have been accepted for presentation during the late-breaking research sessions at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, LA.

Abstracts and full session details can be accessed through the AACR meeting planner: AACR Annual Meeting 2022 | April 8-13, 2022 | New Orleans
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC

BioNTech SE announced the expansion of its strategic collaboration with Tarrytown-headquartered, Regeneron to advance the Company’s FixVac candidate BNT116 in combination with Libtayo® (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement the companies plan to jointly conduct clinical trials to evaluate their combination in different patient populations with advanced NSCLC. Lung cancer is worldwide one of the most common diagnosed malignant cancer types and the leading cause of cancer death. 1 NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers.
Central New York Biotech Accelerator Now Accepting Applications for 2022 Medical Device Innovation Challenge
The CNYBAC Medical Device Innovation Challenge is a 6-month intensive mentorship / network expansion / resource rich program for early-stage innovators. This highly competitive program accepts 5-6 teams each year to participate. To date, 26 teams have graduated from the program and have amassed milestone achievements during and following their participation. The MDIC serves as a complement and a pipeline to other incubation/acceleration programs.
Applications are accepted January 1 through April 30 each year and are reviewed through a due diligence process performed by The Innovation Law Center, Syracuse University. Participants are selected by the MDIC Review Committee - interviews may be convened to assist in team selection. The program starts August 1 (some teams receive early commercialization research in advance of program start). You may participate virtually or on-site. If on-site, you receive 6-months of free work space in the CNYBC Creation Garage, 841 E. Fayette St., Syracuse, NY. All selected teams can utilize this facility at any point in time during the program. 
Biotech & Patient Engagement: More Important Than Ever
NewYorkBIO is holding its second annual Patient Engagement Summit on April 6th, bringing together industry, advocacy organizations, and - most importantly - the patient community for a dialogue on how innovation in healthcare can be more inclusive.

April 6, 2022
9:00am to 1:00pm
Fully virtual, free event

Have good news to share from
Westchester’s biosciences ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.